There has been a lot of news in the area of early access for great drugs to treat advanced prostate cancer prior to the FDA’s approval.
I have informed you about the Early Access Program for MDV-3100 in men with castrate resistant prostate cancer previously treated with a Docetaxel based chemotherapy agent. The latest news of this program is that there has been two (2) new sites added making it available in a total of 22 states.
The early access trial is designed to monitor the drugs safety. Nobody will receive a pacebo and the MDV-3100 will not have a cost to a participants. However, there might be some outside costs, so check with the site where you participate.
To participate in the trial the basic requiements are:
• CRPC/HRPC – on hormone therapy with progressive disease
• 3 weeks since Zytiga (abiraterone)
• Previously treated with Taxotere (docetaxel)
• No small cell or neuroendocrine features